Edwards Lifesciences Corporation Stock News

Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

Upgrades For The Carlyle Group Inc (NASDAQ:CG), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Carlyle Group earned $1.17 in the second quarter, compared to $0.88 in the ye

Roku, Inc. (NASDAQ: ROKU) shares fell 24.3% to $64.45 in pre-market trading after the company reported weaker-than-expected financial results for its second quarter and withdrew its full-year revenue

EW earnings call for the period ending June 30, 2022.

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences Corp (NYSE: EW) reported second-quarter sales of $1.37 billion, flat compared to 2Q21, missing the consensus of $1.4 billion. Adjusted EPS was $0.63, which missed the consensus

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET Company Participants Mark Wilterding - VP, IR and Treasurer Mike Mussallem - Chairman and CEO Scot

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.

IRVINE, Calif. , July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28,

LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.

When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet thes

In the latest trading session, Edwards Lifesciences (EW) closed at $97.45, marking a -1.99% move from the previous day.

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 0 0 0